Volume 28, Number 9—September 2022
Research
Fulminant Transfusion-Associated Hepatitis E Virus Infection Despite Screening, England, 2016–2020
Table 5
Donation no. | HEV viral load, IU/mL† | Components | Recipient details | Recipient follow-up testing results |
---|---|---|---|---|
Donation 1 |
4 |
Platelet 1 | Hospitals informed, no data back |
NA |
Platelet 2 |
||||
Donation 2 |
8 |
Platelet 1 | Hospitals informed, no data back |
NA |
Platelet 2 |
||||
Donation 3 |
<37 |
Platelet 1 | Hospitals informed, no data back |
NA |
Platelet 2 |
||||
Donation 4 |
<37 |
Platelet 1 | Hospitals responded, no evidence of transmission |
NA |
Platelet 2 |
||||
Donation 5 |
37 |
Platelet 1 | M, 50–60 years, B-cell lymphoma | Confirmed transmission |
Platelet 2 |
F, 20-30 y, sepsis |
Deceased |
||
Donation 6 |
37 |
Platelet 1 | F, 60–70 y, aplastic anemia | Tested negative |
Platelet 2 |
M, 50–60 y, lymphoma |
Tested negative |
||
Donation 7 |
4.5 |
Platelet 1 | M, 40–50 y, aplastic anemia | Confirmed transmission |
Platelet 2 |
F, 50–60 y, vascular syndrome |
Tested negative |
||
Donation 8 |
10 |
Platelet 1 | M, 60–70 y, aplastic anemia | Tested negative |
Platelet 2 |
M, <10 y, cancer |
Deceased |
||
Donation 9 | 3 | Platelet 1 | F, 40–50 y, myelodysplastic syndrome | Tested negative |
Platelet 2 | M, 40–50 y, acute myeloid leukemia | Deceased |
*Each donation was tested for HEV RNA and divided into 2 platelet packs. †Estimated viral loads given where available. HEV, hepatitis E virus; NA, not applicable.
Page created: July 14, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.